Founded in 2012, Bionovis was born from the union of the renowned Brazilian laboratories Aché, EMS, Hypera Pharma and União Química. As a pharmaceutical biotechnology joint venture, we have become leaders and pioneers in the national production of highly complex biological medicines and biosimilars.
We have established collaborations with prominent global players in the sector and leading public laboratories in Brazil. Through these strategic alliances, we acquire advanced technologies for the manufacture of innovative biopharmaceuticals, biosimilars, and biobetters.
Today, some of our biopharmaceuticals are in an advanced stage of technology transfer and already serve the Ministry of Health, providing access to high-standard therapies throughout Brazilian territory. This movement reinforces our commitment and our role in strengthening the pharmaceutical biotechnology sector in Brazil.
We have established collaborations with prominent global players in the sector and prominent public laboratories in Brazil. Through these strategic alliances, we acquire advanced technologies for the manufacture of innovative biopharmaceuticals, biosimilars and biobetters.
Today, some of our biopharmaceuticals are in an advanced stage of technology transfer and already serve the Ministry of Health, providing access to high standard therapies in the entire Brazilian territory. This movement reinforces our commitment and position in strengthening the pharmaceutical biotechnology sector in Brazil.
We remain committed to innovating and expanding our portfolio of biopharmaceuticals and biosimilars to offer high-quality medicines to patients in Brazil and abroad.
The pharmaceutical biotechnology joint venture is formed by the union of laboratories Aché, EMS, Hypera Pharma and União Química.
Signed with Janssen-Cilag, owner of the biopharmaceutical Infliximab.
For the production of the biological Interferon beta-1a.
Our Biotech is starting to come to life.
Pilot Plant, Quality Laboratory and logistics operations.
For technology transfer of biosimilar etanercept, supplied to the SUS.
For biosimilar rituximab technology transfer.
For technology transfer of biosimilar trastuzumab.
For golimumab technology transfer.
Start of operations of the industrial plant for the production of biopharmaceuticals.
For technology transfer of biosimilar adalimumab.
For commercialization of pegfilgrastim.
For commercialization of bevacizumab.
We believe that the pursuit of success and efficiency is only valid when business conduct is guided by solid principles of integrity, respect, loyalty, and justice.
We work with the purpose of expanding the Brazilian population’s access to innovative medicines, always in line with the most rigorous scientific, technical, and ethical standards.
Bionovis is a pioneer in the production and commercialization of biological and biosimilar medicines.
Our pursuit of scientific innovations and highly complex medicines aims to build a healthier Brazil — and a healthier world — for everyone.
© 2025 Bionovis. Companhia Brasileira de Biotecnologia Farmacêutica.
